Benchmark Capital Advisors’s BioLineRX BLRX Stock Holding History

Benchmark Capital Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$63K	Hold	238	–	–	0.06%	108
2018 Q3	$153K	Hold	238	–	–	0.12%	121
2018 Q2	$127K	Hold	238	–	–	0.1%	122
2018 Q1	$124K	Hold	238	–	–	0.1%	124
2017 Q4	$156K	Sell	238 -5	-2%	-$3.29K	0.12%	124
2017 Q3	$164K	Buy	243 +3	+1%	+$1.86K	0.13%	128
2017 Q2	$122K	Hold	240	–	–	0.1%	127
2017 Q1	$138K	Buy	240 +167	+229%	+$108K	0.11%	109
2016 Q4	$40K	Hold	73	–	–	0.03%	121
2016 Q3	$51K	Hold	73	–	–	0.04%	126
2016 Q2	$35K	Sell	73 -5	-6%	-$2.8K	0.03%	124
2016 Q1	$48K	Hold	78	–	–	0.04%	118
2015 Q4	$61K	Hold	78	–	–	0.05%	116
2015 Q3	$72K	Sell	78 -44	-36%	-$47K	0.06%	121
2015 Q2	$194K	Buy	122 +55	+82%	+$68.1K	0.14%	116
2015 Q1	$84K	Hold	67	–	–	0.06%	122
2014 Q4	$65K	Hold	67	–	–	0.04%	118
2014 Q3	$62K	Hold	67	–	–	0.04%	117
2014 Q2	$83K	Buy	67 +34	+103%	+$42.6K	0.05%	119
2014 Q1	$45K	Buy	+33	New	+$54.3K	0.03%	123

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

Benchmark Capital Advisors's BLRX Position: Q4 2018 in Review

Benchmark Capital Advisors held its BioLineRX (BLRX) position steady in Q4 2018 at 238 shares worth $63K. The position accounts for 0.06% of the portfolio, ranked #108.

Benchmark Capital Advisors first reported a position in BLRX in Q1 2014 and has held it in 20 quarters since. The position peaked at $194K in Q2 2015. 34 funds tracked by Wall St. Rank hold BLRX as of Q4 2018.

Benchmark Capital Advisors held 238 shares of BioLineRX worth $63K as of Q4 2018.
Benchmark Capital Advisors left its BioLineRX share count unchanged in Q4 2018.
BioLineRX made up 0.06% of Benchmark Capital Advisors's portfolio in Q4 2018, its #108 holding.
Benchmark Capital Advisors first reported a position in BioLineRX in Q1 2014 and has held it in 20 quarters since.
Benchmark Capital Advisors's BioLineRX position peaked at $194K in Q2 2015.
34 funds tracked by Wall St. Rank held BioLineRX as of Q4 2018.

Based on Benchmark Capital Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.